
Scegli la tua etichetta
mostrata direttamente sul flaconcinoDapagliflozin (Forxiga)
Medication
- Spedito dalla Germania
Ordine
- DHL con tracciamento
- Imballaggio discreto
In sintesi
Dapagliflozin (Forxiga) in cifre
I dati chiave dalla nostra enciclopedia. Trascina il punto lungo la curva per vedere quanto resta dopo una dose, secondo il calcolo.
Voce completa dell'enciclopediaHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~12.9 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about12.9hours
- Class
- SGLT2 inhibitorgliflozin, selective
- Use
- Oral1x daily
- Sizes
- 10 mg1 size in the shop
What studies show
All 6 sources in the lexicon- McMurray et al., NEJM, 2019
Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58) (opens in a new tab)
Wiviott et al., NEJM, 2019Euglycemic diabetic ketoacidosis as a complication of SGLT2 inhibition (opens in a new tab)
Peters et al., Diabetes Care, 2015
Recensioni
Cosa dicono i clienti
Solo ordini reali che includevano Dapagliflozin (Forxiga).
Tutte le recensioniNon esiste ancora un'analisi di laboratorio per Dapagliflozin (Forxiga). Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio
Conoscenze
Tutto su Dapagliflozin (Forxiga)
Informazioni dettagliate in arrivo.
How does dapagliflozin work?
It blocks the transporter SGLT2 in the kidney, which brings filtered sugar back into the blood. The sugar then leaves with the urine without insulin being needed. Breakdown runs mainly via the enzyme UGT1A9 to an inactive metabolite.
Does it help without diabetes?
In the trials on heart failure and chronic kidney disease the effect was similar with and without diabetes. With reduced pumping the risk of worsening or cardiac death fell by 26 percent.
What did the kidney trial show?
Among 4,304 participants 9.2 percent on dapagliflozin and 14.5 percent on placebo had an event (halved kidney function, kidney failure or death). 19 had to be treated to prevent one. The trial was therefore stopped early.
What is euglycaemic ketoacidosis?
Acidosis from ketones with nearly normal blood sugar. Because sugar does not rise much, it was recognised late in a case series. The authors advise checking ketones in case of nausea, vomiting or malaise. In the large diabetes trial it occurred in 0.3 versus 0.1 percent.
Does it lower heart attacks and strokes?
Not clearly in the diabetes trial with 17,160 patients: 8.8 versus 9.4 percent major cardiovascular events. Hospital stays for heart failure and kidney events did fall clearly.
Which side effects are known?
Serious genital infections or those leading to a stop occurred in 0.9 versus 0.1 percent, ketoacidosis in 0.3 versus 0.1 percent. In the heart failure trials volume depletion, kidney problems and low blood sugar were not more common than on placebo.
Correlati
Prodotti correlati
Telmisartan
Farmaci · Cardiovascolare Cardiovascolare
2 misure
Testato in laboratorio
Ivermectin
Farmaci · Stomaco e fegato Stomaco e fegato
1 misura
Fenbendazol
Farmaci · Stomaco e fegato Stomaco e fegato
1 misura
Prednisone
Farmaci · Stomaco e fegato Stomaco e fegato
1 misura
Dapagliflozin (Forxiga)